Navigation Links
SPX Completes Acquisition of Anhydro
Date:7/21/2010

CHARLOTTE, N.C., July 21 /PRNewswire-FirstCall/ -- SPX Corporation (NYSE: SPW) today announced that it has completed the acquisition of the Anhydro business, a Soeborg, Denmark-based global supplier of liquid concentration equipment, powder processing solutions, and dewatering plants and equipment.  The terms of the transaction were not disclosed.

Anhydro supplies a wide range of evaporation and drying solutions for dairy, food, and starch producers and for the chemical and pharmaceutical industries worldwide.  The transaction includes all Anhydro's business units with the exception of its Danish Filter business, Simatek A/S, and its German, U.K. and U.S. operations, as well as certain individual projects. The acquired business units employ 225 employees and are expected to generate 2010 full-year revenue of approximately 85 million Euros.

"The addition of Anhydro broadens our technology equipment offerings and systems capabilities and strengthens our ability to serve customers in the global food, pharmaceutical and chemical processing end markets," said SPX Chairman, President and Chief Executive Officer Christopher J. Kearney. "This strategic transaction also builds on our recent acquisition of Gerstenberg Schroder and underscores our commitment to expanding our Flow Technology segment, which remains a key component of our global growth strategy."

SPX first announced that it had entered into a definitive agreement to acquire Anhydro on June 18, 2010.  Anhydro will operate within SPX's Flow Technology segment.

About SPX

SPX Corporation (NYSE: SPW) is a Fortune 500 multi-industry manufacturing leader that provides its customers with highly-specialized, engineered solutions to solve critical business issues.

SPX products and technologies play an important role in the expansion of global infrastructure to help meet increased demand for power and energy and support many different sources of power generation, including coal and natural gas, nuclear, solar and geothermal. The company's innovative product portfolio, containing many energy efficient products, includes cooling systems for power plants throughout the world; highly advanced food processing components and turnkey, scalable systems serving the global food and beverage industry; process equipment that assists a variety of flow processes including oil and gas exploration, distribution and refinement and power generation; handheld diagnostic tools that aid in vehicle maintenance and repair; and power transformers that allow utility companies to regulate electric voltage, transmission and distribution.

With headquarters in Charlotte, North Carolina, SPX has 15,000 employees in more than 35 countries worldwide. Visit www.spx.com.

Certain statements in this press release including any statements relating to post-acquisition results, may be forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. Please refer to our public filings for a discussion of certain important factors that relate to forward-looking statements contained in this press release. The word "expect," "believe" and similar expressions may identify forward-looking statements. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Statements in the press release speak only as of the date of this press release, and SPX disclaims any responsibility to update or revise such statements.


'/>"/>
SOURCE SPX Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Bernstein Liebhard LLP today announced that a securities class ... for the District of Arizona on ... or entities who purchased common shares of Insys Therapeutics Inc. ... 3, 2015 through January 25, 2016 (the "Class Period").  The ... of the Securities Exchange Act of 1934.  ...
(Date:2/4/2016)... 4, 2016 Wegener Polyangiitis - Pipeline ... Direct,s, ,Wegener Polyangiitis - Pipeline Review, H2 2015, ... pipeline. This report provides comprehensive information on ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ...
(Date:2/4/2016)... 2016 Summary Breast cancer, a malignant ... most common cancer in women worldwide, accounting for 16% ... The number of women diagnosed with breast cancer has ... of deaths has declined due to earlier diagnosis and ... revolutionized in the past four decades, especially with increasing ...
Breaking Medicine Technology:
(Date:2/6/2016)... (PRWEB) , ... February 06, 2016 , ... Shark ... to announce the launch of a new DRTV campaign with Belly Bands. , Having ... tried everything from sprays to puppy pads and find nothing works, get Belly ...
(Date:2/5/2016)... ... ... Love is in the air at King Kullen! The local grocer is ... staple for Valentine’s Day is a must-have, and can be picked up with all ... are long-stem roses available, but also other flower bouquets, elegantly wrapped and ready to ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... and setting the stage for new clinical and scientific initiatives have all marked ... after she was appointed President and CEO of the nation’s oldest cancer center, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco ... micro-needling services in their Napa Valley office. The technique utilizes the body’s own ... Dr. Canales and Dr. Furnas, are part of only a select few cosmetic ...
(Date:2/5/2016)... ... ... After years as an active staff surgeon and having served as the director ... transitioned to chief of the Division of Plastic Surgery at what is now known ... began a second three-year term in January of 2016. , The original selection was ...
Breaking Medicine News(10 mins):